Stephen V Liu, Associate Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Report on time to symptomatic progression from phase III MARIPOSA study in EGFR mutant NSCLC available. Median was 43.6m with 1L amivantamab + lazertinib compared to 29.3m with osimertinib (HR 0.69). TTSP strongly correlated with PFS and OS.”
Title: Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer
Authors: Danny Nguyena, Se-Hoon Lee, Shun Lu, Nicolas Girard, Chien-Chung Lin, Enriqueta Felip, Andres Aguilar, Chaiyut Charoentum, Felipe Melo Cruz, Hiroaki Akamatsu, Ruben Kowalyszyn, Cagatay Arslan, Martin D. Forster, Damien Urban, Daniel Misch, Lizbett Vanessa García Montes, Shirish M. Gadgeel, Marcia Cruz-Correa, Scott Owen, Wolfgang Schuette, Jan Sermon, Ronja Kerßenboom, Markus Frosien, Janka Meißner, Priya Ord, Mariah Ennis, Elizabeth Fennema, Seema Sethi, Joshua M. Bauml, Mahesh Daksh, Byoung Chul Cho.
Read the full article.
To which David Gandara, Director, Thoracic Oncology at UC Davis Comprehensive Cancer Center, added:
“Re MARIPOSA trial, thanks Stephen V Liu for important update. Helps define long-term risk versus benefit for this regimen. I am convinced that there is rationale for looking toward the ‘light at the end of the tunnel’. Was data on ctDNA included?”
You can also read:
